The government has expressed guarded optimism that United States investment in the country will not be affected by a delay of US President Barack Obama’s visit to Indonesia.Coordinating Minister for the Economy Hatta Rajasa told Antara on Friday Ame US investment unaffected by Obama’s delayed trip to RI

Go here to see the original:
US investment unaffected by Obama’s delayed trip to RI

MELBOURNE, March 19 – Australian stocks were flat to weaker in opening trade on Friday, with slight losses for financial stocks and softness in resources stocks after commodity prices eased. The benchmark S&P/ASX 200 index eased 7.85 points at 233 Australia shares softer miners slip; NZ dips

Read the original post:
Australia shares softer miners slip; NZ dips

The current US administration does not seem to regard contracts as “a deal is a deal” when the other party is the owner of capital. Bond holders took the pipe in the auto company bankruptcies at the hands of the administration.  In the Congress, Barney Franks talked tough about bank bond holders perhaps needing to take

Original post:
When is a Contract a Contract?

Investment firm T. Rowe Price Group Inc. (TROW) is in advanced talks to buy a stake in Asset Management Co. (“China AMC”) from its holding company Citic Securities. Citic Securities, which is aggressively seeking licenses for …

Read more:
(TROW) T. Rowe Price Group to Buy a Stake in China’s Largest Fund Management Firm

Following the release of Ciena Corporation’s (CIEN) first quarter fiscal 2010 results on March 4, 2010, analysts have made both positive and negative revisions to their estimates. Linthicum, Maryland-based CIENA is an original equipment manufacturer (OEM) …

Read the rest here:
(CIEN) Ciena Analysts Maintain Neutral Ratings After Revisions

China Sunergy just announced the purchase of 2 solar module manufacturers, CEEG (Shanghai) Solar Science & Technology Co., Ltd and CEEG (Nan Jing) New Energy Co., Ltd, for a total price of approximately $47 million. The company is funding the transaction on its own, and will pay for the acquisitions in a series of installments. CEEG

Visit link:
China Sunergy (CSUN) Buys 2 Solar Module Manufacturers for $47 Million

RICHMOND, Va., March 17 /PRNewswire-FirstCall/ Dominion will host an analyst meeting at The Waldorf=Astoria in New York on Friday, May 7, 2010 from 10:00 a.m. to 12:00 p.m. EDT.Dominion management will discuss its business strategy and provide deta Dominion To Host Analyst Meeting

See the rest here:
Dominion To Host Analyst Meeting

Isis Pharmaceuticals, Inc. ( ISIS ) and Genzyme Corp. ( GENZ ) recently announced the publication of phase III data on mipomersen in The Lancet. The data was published from a study that was conducted in patients with homozygous familial hypercholesterolemia (hoFH).  Results, which were presented at the annual American Heart Association meeting in November 2009, showed that mipomersen met its primary endpoint. The candidate achieved a 25% reduction in low-density lipoprotein – cholesterol (LDL-C) in an intent-to-treat analysis.  Besides meeting the primary endpoint, the study also met each of its secondary and tertiary endpoints, which included statistically significant reductions in apolipoprotein-B, total cholesterol, non- high-density lipoprotein (HDL) cholesterol, lipoprotein (a) [Lp(a)], very low density lipoprotein-cholesterol (VLDL-C) and triglycerides.  Mipomersen is Isis’ lead pipeline candidate. It is an antisense drug that targets apolipoprotein B (apoB) -100, which is critical to the synthesis and transport of low density lipoprotein (LDL) or bad cholesterol. By potentially knocking out the apoB-100 protein via antisense technology, Isis scientists believe they can effectively lower the cholesterol of patients and reduce the risk of serious cardiovascular disease.  Genzyme intends to file for approval in the U.S. and EU in the first half of 2011 for the treatment of patients with homozygous FH (hoFH), which represents a much smaller patient population. hoFH is a very rare condition that is estimated to affect about 1 in a million people.  Given the novel mechanism and narrow initial market focus of homozygous (Ho) FH, the US Food and Drug Administration (FDA) granted mipomersen orphan drug status.  Isis and Genzyme stated that

Read the rest here:
Isis Drug Phase III Data Published – Analyst Blog

Validus Holdings, Ltd. ’s ( VR ) MACD indicator has moved into bearish territory with a reading of -0.1673. The Zacks #4 Rank (“Sell”) stock declined slightly to $25.84 in morning trade. The Zacks Consensus Estimate on the company’s earnings for 2010 has reduced by 93 cents over the past week to $3.48 per share. “VR” Free Stock Analysis: Buy? Sell? Hold? Zacks Investment Research

Read more:
Bearish MACD for Validus – Zacks Tale of the Tape

Appetite for risk is being fueled by the Fed, BOJ and EU support for Greece. Even Standard and Poor’s has given Greece’s austerity budget cuts their stamp of approval. Before, that ‘sign of approval’ would …

View original post here:
EU officials throw Greece a small life preserver

Russia’s economy could grow faster than expected this year; by as much as 4-4.5% in comparison with predictions of 3-3.5%.  See Bloomberg for Russia’s three-pronged strategy to facilitate the economic recovery, currently jeopardized by th…

Read the original here:
Today in Russian Business – March 17, 2010

Antoine van Agtmael (pictured), the Chairman and CIO of Emerging Markets Management (EMM), and whom Bloomberg credits with coining the term “emerging markets” back in 1981, opined that while equities among developing nations are probably fairly valued (the corresponding MSCI trades at 12.8x estimated earnings for 2010, compared with its four-year average of 12.1), small caps

Original post:
Van Agtmael singles out small caps, Qatar and Saudi Arabia for 2010